Vaccines

Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

Retrieved on: 
Monday, September 28, 2020
Oncology, Health, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Life sciences, Branches of biology, Articles, Medical research, Vaccines, Moderna, RNA, Messenger RNA, Vaccine, Arcturus Therapeutics

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Stephen Hoge, President, will participate in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020 at 2:00 p.m.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Stephen Hoge, President, will participate in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020 at 2:00 p.m.
  • A live webcast will be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
  • Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

WhyWeVax™ Announces the Creation of a Scientific Advisory Board and Six New Members

Retrieved on: 
Monday, September 28, 2020
Medical specialties, Vaccination, Medicine, Vaccine, Virology, Clinical medicine, Vaccines, RTT

SAN FRANCISCO, Sept. 28, 2020 /PRNewswire/ --Why We Vaccinate, Inc., a 501(3)(c) educational organization dedicated to providea credible and trusted source for honest and factual information on vaccines, their efficacy, safety and importance to public health, announced today the creation of its Scientific Advisory Board (SAB) and the appointment of six new members.

Key Points: 
  • SAN FRANCISCO, Sept. 28, 2020 /PRNewswire/ --Why We Vaccinate, Inc., a 501(3)(c) educational organization dedicated to providea credible and trusted source for honest and factual information on vaccines, their efficacy, safety and importance to public health, announced today the creation of its Scientific Advisory Board (SAB) and the appointment of six new members.
  • "The appointment of these highly decorated scientists, administrators and research professionals will provide WhyWeVaxwith the scientific vision and leadership to further the goals and overall mission of the organization," states Michael Olin, Chairman of the Scientific Advisory Board and Board member of WhyWeVax.
  • "These are challenging times for the scientific and vaccine communities, and we will work to engage and support them through the dissemination of clear and factual information on the value of vaccines and immunization for our communities' health and welfare."
  • The new Scientific Advisory Board members include:

Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

Retrieved on: 
Monday, September 28, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical research, Medicine, Health, Respiratory diseases, COVID-19 vaccine, Biomedical Advanced Research and Development Authority, Barda, CoV, Severe acute respiratory syndrome, Vaccines, Terra CoV-2, Oragenics, Inc.

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2.
  • Oragenics has been informed by the Biomedical Advanced Research and Development Authority (BARDA) of BARDAs determination not to enter into negotiation with the Company.
  • Although we are disappointed with BARDAs funding decision, we will continue to pursue other sources of non-dilutive funding of grants and corporate partnerships, and possibly equity capital to advance development of our promising vaccine.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Enesi Pharma Appoints Vaccine Development Expert Dr Keith Howard as Chief Scientific Officer to Lead Research & Development of Novel ImplaVax® Solid-dose, Needle-free Vaccination Products

Retrieved on: 
Monday, September 28, 2020
Medical specialties, Health, Vaccines, Articles, Vaccine, Virology, Vaccination, RTT, PATH

Dr Howard is a seasoned vaccine development expert who will lead Enesi's R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.

Key Points: 
  • Dr Howard is a seasoned vaccine development expert who will lead Enesi's R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.
  • Prior to joining Enesi, Dr Howard was Chief Development Officer at Oxford-based Vaccitech, where he was the head of R&D, process development and manufacturing for its novel viral vector vaccine programmes.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.
  • Our ImplaVax-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats.

Enesi Pharma Appoints Vaccine Development Expert Dr Keith Howard as Chief Scientific Officer to Lead Research & Development of Novel ImplaVax® Solid-dose, Needle-free Vaccination Products

Retrieved on: 
Monday, September 28, 2020
Medical specialties, Health, Vaccines, Articles, Vaccine, Virology, Vaccination, RTT, PATH

Dr Howard is a seasoned vaccine development expert who will lead Enesi's R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.

Key Points: 
  • Dr Howard is a seasoned vaccine development expert who will lead Enesi's R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.
  • Prior to joining Enesi, Dr Howard was Chief Development Officer at Oxford-based Vaccitech, where he was the head of R&D, process development and manufacturing for its novel viral vector vaccine programmes.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.
  • Our ImplaVax-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats.

Pneumococcal Vaccine Market Research Report by Type, by Indication, by Product, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Friday, September 25, 2020
Medical specialties, Vaccination, Vaccines, Health, Virology, Medicine, Pneumococcal vaccine, RTT, Vaccine, Global health, Gavi

Based on Distribution, the Pneumococcal Vaccine Market studied across Government Authorities and Non-governmental Organizations.

Key Points: 
  • Based on Distribution, the Pneumococcal Vaccine Market studied across Government Authorities and Non-governmental Organizations.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Pneumococcal Vaccine Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pneumococcal Vaccine Market?
  • What are the modes and strategic moves considered suitable for entering the Global Pneumococcal Vaccine Market?

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

Retrieved on: 
Friday, September 25, 2020
Health, Medicine, Medical specialties, Medical research, Vaccines, Vaccination, Vaccine, Virology, Adjuvant

Vaccine design was based on large sets of data obtained during the analysis of IPA's SARS-CoV-2 therapeutic programs.

Key Points: 
  • Vaccine design was based on large sets of data obtained during the analysis of IPA's SARS-CoV-2 therapeutic programs.
  • In parallel to the pre-clinical study, which is supported through TRANSVAC2 (EC-funded project,grant agreement N 730964), IPA and LiteVax are initiating relevant ex vivo assays.
  • The study results will be compiled by November 2020 and will allow the companies to prioritize subsets of ideal vaccine candidates for further development.
  • The companies expect that the combination of IPA's vaccine with LiteVax's adjuvant technology, designed to specifically enhance the host's immune response, will have a significant impact toward a successful single-low-dose vaccine against SARS-CoV-2.

Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Retrieved on: 
Friday, September 25, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Vaccination, Health, Medical specialties, Medicine, Vaccines, Virology, Medical research, Adjuvants, Vaccine, Reactogenicity, H5N1 clinical trials, COVID-19 vaccine, Clover Biopharmaceuticals, COVID-19 S-Trimer Vaccine, Trimer-Tag© Technology

We are proud to be collaborating with Clover on the development of this vaccine for COVID-19, and are committed to supporting Clover in making the vaccine available globally.

Key Points: 
  • We are proud to be collaborating with Clover on the development of this vaccine for COVID-19, and are committed to supporting Clover in making the vaccine available globally.
  • These positive preclinical data supported the decision to progress adjuvanted vaccine candidates using both adjuvants into Clovers ongoing Phase 1 clinical study of S-Trimer in healthy adult and elderly participants.
  • The trial is a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine at multiple dose levels.
  • Clover intends to initiate a global Phase 2/3 vaccine efficacy study before the end of 2020.

Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine

Retrieved on: 
Thursday, September 24, 2020
Health, Medicine, Vaccination, Vaccines, Medical research, COVID-19 vaccine, Novavax, Influenza vaccines, Coalition for Epidemic Preparedness Innovations, Vaccine, Cepi, Cepi

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

Key Points: 
  • BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
  • NVXCoV2373 is a vaccine candidate engineered from the genetic sequence of SARSCoV2, the virus that causes COVID-19 disease.
  • Novavaxhas secured$2 billionin funding for its global coronavirus vaccine program, including up to$388 millionin funding from theCoalition for Epidemic Preparedness Innovations(CEPI).

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

Retrieved on: 
Thursday, September 24, 2020
Health, Medical specialties, Novavax, Vaccination, Vaccines, Vaccine, Clinical trial, COVID-19 vaccine

The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries.

Key Points: 
  • The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries.
  • NVX-CoV2373 is a stable, prefusion protein made using Novavax recombinant protein nanoparticle technology that includes Novavax proprietary MatrixM adjuvant.
  • NVX-CoV2373 is also being evaluated in two ongoing Phase 2 studies, which began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.